Hospital
Sutter Valley Hospitals
Sutter Valley Hospitals was paid $76.21M by Medicaid between Jan 2018 and Nov 2024, across 240 billing codes. Its largest line is 0450, Emergency room services — 28% of everything it billed.
33Billing provider infoSUTTER VALLEY HOSPITALS
MODESTO, CA 95355
MODESTO, CA 95355
33aNPI1699129601assigned 04/15/2016
33bProvider typeGeneral Acute Care Hospital
28Total paid$76.21M
24GClaims1,403,854
24DCodes billed240
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#33 of 410
Median peer was paid$6.90M
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 199,936 | $11.00M | |
| 2019 | 183,189 | $8.48M | |
| 2020 | 176,196 | $10.70M | |
| 2021 | 218,740 | $13.69M | |
| 2022 | 258,254 | $12.96M | |
| 2023 | 263,279 | $12.52M | |
| 2024incomplete | 104,260 | $6.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 28% | 192,336 | 167,945 | $21.33M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.8% | 12,079 | 11,655 | $5.17M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.6% | 30,652 | 27,576 | $2.74M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 10,562 | 10,180 | $2.53M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.6% | 11,687 | 11,347 | $1.98M |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.6% | 4,414 | 4,283 | $1.95M |
| 80053 | Comprehensive metabolic panel | 2.1% | 103,885 | 92,412 | $1.61M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.0% | 9,193 | 8,962 | $1.55M |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.0% | 24,058 | 20,524 | $1.52M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.9% | 1,648 | 748 | $1.43M |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.9% | 2,267 | 2,182 | $1.43M |
| 0762 | 1.7% | 1,588 | 879 | $1.31M |
228 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 38,687 | $1.27M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.7% | 23,581 | $1.27M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 11,457 | $1.15M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 114,520 | $1.06M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 16,180 | $1.04M |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 31,938 | $953K |
| 0160 | 1.1% | 1,574 | $876K | |
| 0270 | 1.1% | 22,233 | $845K | |
| 99284 | Emergency room visit (serious) | 1.1% | 4,854 | $841K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 7,138 | $837K |
| 99285 | Emergency room visit (most serious) | 1.0% | 2,944 | $799K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 19,276 | $776K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 19,053 | $722K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,306 | $687K |
| J3490 | Unclassified drugs | <1% | 20,041 | $673K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 13,325 | $646K |
| 0250 | <1% | 44,118 | $589K | |
| 82077 | <1% | 5,352 | $521K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 6,283 | $518K |
| 99283 | Emergency room visit (moderate) | <1% | 3,320 | $477K |
| Z7502 | <1% | 12,970 | $464K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,616 | $457K |
| 71045 | Radiologic examination, chest; single view | <1% | 16,627 | $411K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 4,272 | $405K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,539 | $392K |
| 84484 | <1% | 34,619 | $384K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 87 | $365K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,899 | $346K |
| 99199 | Unlisted special service, procedure or report | <1% | 874 | $343K |
| 83690 | <1% | 39,409 | $340K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,074 | $334K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,043 | $333K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,150 | $326K |
| 96376 | <1% | 689 | $308K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,275 | $302K |
| 93971 | <1% | 2,181 | $298K | |
| 76801 | <1% | 3,386 | $281K | |
| 80143 | <1% | 2,772 | $267K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,466 | $251K |
| 81001 | <1% | 56,167 | $248K | |
| 80179 | <1% | 2,675 | $248K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,886 | $242K |
| 70486 | <1% | 688 | $229K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,749 | $228K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 385 | $227K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 17,399 | $226K |
| 83880 | <1% | 6,625 | $221K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 603 | $220K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,285 | $220K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,590 | $198K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 16,064 | $184K |
| 76830 | Ultrasound, transvaginal | <1% | 2,158 | $179K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,145 | $178K |
| 82803 | <1% | 5,819 | $177K | |
| 81025 | <1% | 24,336 | $177K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,647 | $175K |
| 73030 | <1% | 2,889 | $170K | |
| 73562 | <1% | 3,654 | $167K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 11,250 | $155K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,313 | $140K |
| 90715 | <1% | 1,804 | $138K | |
| 73630 | <1% | 3,648 | $135K | |
| 73130 | <1% | 2,828 | $133K | |
| 73610 | <1% | 3,210 | $130K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,077 | $129K |
| 87040 | <1% | 9,221 | $128K | |
| 83605 | <1% | 8,127 | $121K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,294 | $102K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,117 | $101K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,151 | $98K |
| 84702 | <1% | 6,644 | $98K | |
| 85730 | <1% | 7,200 | $95K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,530 | $94K |
| 83735 | <1% | 11,553 | $91K | |
| 0510 | <1% | 2,468 | $89K | |
| 84703 | <1% | 11,007 | $89K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,120 | $87K |
| 87634 | <1% | 1,329 | $85K | |
| 73110 | <1% | 1,796 | $82K | |
| 72100 | <1% | 1,966 | $81K | |
| 85610 | <1% | 9,773 | $68K | |
| 86901 | <1% | 6,671 | $66K | |
| 86900 | <1% | 6,929 | $63K | |
| 86850 | <1% | 3,575 | $63K | |
| 87186 | <1% | 4,535 | $58K | |
| 82330 | <1% | 3,084 | $58K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,342 | $56K |
| 73080 | <1% | 1,137 | $56K | |
| 73590 | <1% | 1,163 | $50K | |
| 0761 | <1% | 1,083 | $47K | |
| 70496 | <1% | 188 | $47K | |
| 73502 | <1% | 1,014 | $46K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 121 | $46K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,869 | $45K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,204 | $44K |
| 87077 | <1% | 3,995 | $44K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,629 | $42K |
| 85379 | <1% | 3,297 | $41K | |
| 93458 | <1% | 62 | $41K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 306 | $41K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 200 | $40K |
| 76870 | <1% | 548 | $38K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,603 | $38K |
| 82947 | <1% | 5,723 | $36K | |
| 73090 | <1% | 739 | $35K | |
| 70491 | <1% | 140 | $35K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,931 | $34K |
| 87400 | <1% | 2,994 | $29K | |
| 93970 | <1% | 147 | $29K | |
| 74019 | <1% | 841 | $28K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,726 | $28K |
| 84145 | <1% | 1,188 | $27K | |
| 70498 | <1% | 138 | $27K | |
| 86140 | <1% | 3,981 | $27K | |
| 96415 | <1% | 750 | $26K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 57 | $26K |
| 0760 | <1% | 600 | $26K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,999 | $25K |
| 81003 | <1% | 7,646 | $24K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 283 | $23K |
| 87081 | <1% | 2,499 | $23K | |
| 87430 | <1% | 1,654 | $21K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,317 | $20K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 120 | $19K |
| 73140 | <1% | 788 | $18K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,018 | $17K |
| 96367 | <1% | 354 | $15K | |
| 71020 | <1% | 331 | $15K | |
| 76770 | <1% | 153 | $15K | |
| 84132 | <1% | 1,872 | $13K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 402 | $12K |
| 87210 | <1% | 1,934 | $12K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,012 | $11K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 25 | $11K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 77 | $10K |
| 82550 | <1% | 1,351 | $10K | |
| 86923 | <1% | 62 | $10K | |
| 94644 | <1% | 298 | $9K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,141 | $9K |
| 29125 | <1% | 13 | $9K | |
| 84295 | <1% | 1,332 | $9K | |
| 93798 | <1% | 297 | $9K | |
| L0172 | Cervical, collar, semi-rigid thermoplastic foam, two-piece, prefabricated, off-the-shelf | <1% | 104 | $9K |
| 87088 | <1% | 858 | $9K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 488 | $8K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 51 | $8K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 157 | $8K |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 80 | $8K |
| 87420 | <1% | 1,381 | $8K | |
| 72040 | <1% | 139 | $8K | |
| 74018 | <1% | 309 | $8K | |
| 84100 | <1% | 1,518 | $8K | |
| 72141 | <1% | 13 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,155 | $7K |
| 73552 | <1% | 144 | $7K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 646 | $7K |
| 71250 | <1% | 39 | $7K | |
| 85652 | <1% | 1,931 | $6K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 361 | $6K |
| 87581 | <1% | 184 | $6K | |
| 87486 | <1% | 184 | $6K | |
| 72131 | <1% | 28 | $6K | |
| Z7610 | <1% | 704 | $5K | |
| 73060 | <1% | 151 | $5K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 139 | $5K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 284 | $4K |
| 81002 | <1% | 1,356 | $4K | |
| 80076 | <1% | 321 | $4K | |
| 87150 | <1% | 13 | $4K | |
| 86592 | <1% | 804 | $4K | |
| 93017 | <1% | 122 | $4K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 182 | $4K |
| 71010 | <1% | 115 | $4K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 256 | $4K |
| 82009 | <1% | 690 | $3K | |
| 72070 | <1% | 75 | $3K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 1,340 | $3K |
| 86308 | <1% | 603 | $3K | |
| 0324 | <1% | 38 | $3K | |
| 80061 | Lipid panel | <1% | 347 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 471 | $3K |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 70 | $2K |
| 82553 | <1% | 256 | $2K | |
| 72170 | <1% | 86 | $2K | |
| 84439 | <1% | 244 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 99 | $2K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 109 | $2K |
| 87147 | <1% | 352 | $2K | |
| 99070 | <1% | 128 | $2K | |
| Z9725 | <1% | 41 | $2K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 452 | $2K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 158 | $1K |
| 87045 | <1% | 110 | $1K | |
| 87070 | <1% | 150 | $1K | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 12 | $1K |
| 87205 | <1% | 267 | $1K | |
| 87427 | <1% | 97 | $1K | |
| 97139 | <1% | 24 | $1K | |
| 97750 | <1% | 31 | $1K | |
| 87046 | <1% | 169 | $1K | |
| 71101 | <1% | 26 | $1K | |
| 87899 | <1% | 141 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 130 | $1K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 92 | $964.37 |
| 10060 | <1% | 31 | $900.00 | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 13 | $886.50 |
| 87015 | <1% | 97 | $819.11 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 13 | $780.89 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 358 | $650.98 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 33 | $628.31 |
| 82140 | <1% | 53 | $599.82 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 108 | $539.94 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 15 | $508.51 |
| 73660 | <1% | 24 | $507.98 | |
| 85002 | <1% | 17 | $464.35 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 24 | $401.82 |
| 0636 | <1% | 258 | $211.88 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 39 | $209.38 |
| 84550 | <1% | 29 | $124.13 | |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | <1% | 38 | $123.63 |
| 85027 | <1% | 15 | $100.90 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 133 | $93.82 |
| 87324 | <1% | 12 | $57.04 | |
| 0250R | 0% | 80 | $0.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 14 | $0.00 |
| 0272R | 0% | 99 | $0.00 | |
| 59025 | Fetal non-stress test | 0% | 131 | $0.00 |
| 0360 | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTERRA, PAIGE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Sutter Valley Hospitals | Los Banos, CA | $26.09M |
| Sutter Coast Hospital | Crescent City, CA | $21.67M |
| Sutter Valley Hospitals | Tracy, CA | $19.42M |
| Sutter Valley Hospitals | Los Banos, CA | $17.26M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.